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Objectives: We investigated omeprazole's effect on
'''C-urea breath testing. We also determined the dura-
tion of omeprazole's effect on the breath test. Finally, we
studied whether effects on breath testing were dose de-
pendent. Methods: Fifty-seven employees and outpa-
tients were screened for Helicobacter infection. Those
positive for serology, CLO, or histology were asked to
undergo baseline breath testing. Those with a positive
breath test took omeprazole 20 mg/day for 14 days fol-
lowed by repeat breath testing 1, 3, and 5 days after
therapy. Subjects with persistently positive breath tests
despite omeprazole 20 mg/day were asked to take ome-
prazole 20 mg b.Ld. for 14 days. Repeat breath tests were
performed as above. Results: Thirteen of 57 had HP
infection. Ten of 13 underwent a baseline breath test.
Eight of 10 with baseline breath tests experienced a
significant decrease in expired ""COj after omeprazole
20 mg/day. Five of 13 with active HP infection developed
a negative breath test after omeprazole. All subjects had
a positive breath test within 5 days of stopping omepra-
zole 20 mg/day. Five of eight with persistently positive
breath tests despite omeprazole 20 mg/day took omepra-
zole 40 mg/day. Four of five developed a significant
decrease in '̂'COz excretion after omeprazole. All sub-
jects had a positive breath test within 5 days of stopping
omeprazole 40 mg/day. Conclusions: Recent treatment
with omeprazole 20 mg/day led to false-negative breath
tests in 38.5%. This effect appeared to be dose dependent
and lasted up to 5 days after cessation of omeprazole.
INTRODUCTION
Helicobacter pylori (HP) has emerged as an important
factor in the pathogenesis of peptic ulcer disease and gastric
carcinoma (1, 2), A number of diagnostic modalities are
available to establish the presence of HP infection. Methods
that rely upon the direct demonstration of the organism
include histology and culture. Indirect methods identify
HP's characteristic urease activity (CLO or urea breath
testing) or demonstrate an antibody response to the organ-
ism (serological testing) (3),
Breath testing provides a means of documenting the pres-
ence of HP before or after specific therapy. Urea breath tests
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identify HP by virtue of its urease activity, C- or C-
labeled urea is swallowed by the patient. If urease is present,
urea is cleaved to form HCO^ and NH4^, Ammonium is
sequestered in gastric acid, but HCO^ diffuses into the
blood stream and is expired from the lungs in the form of
labeled CO2, Breath tests are noninvasive, reproducible,
relatively inexpensive, and easy to perform. They have been
found to be both sensitive and specific in the diagnosis of
HP infection (3,4), In the United States, neither the '^C-urea
nor "*C-urea breath test is currently approved for clinical
use by the FDA, However, experts agree that breath testing
in some form will soon become an important and widely
utilized tool for the diagnosis of HP (4),
A number of factors can negatively affect the accuracy of
the urea breath test, including the recent use of agents with
anti-HP activity (4), Omeprazole is a proton pump inhibitor
that is commonly used for the treatment of various acid-
peptic disorders, Omeprazole reportedly has anti-HP prop-
erties, probably related to its potent acid-suppressive effects,
as well as via possible effects on the bacterial H"'"/K"̂
ATPases (5), Because of this anti-HP effect, investigators
have found that omeprazole therapy taken at the time of
breath testing may cause false-negative results. This obser-
vation has been based upon the experience of a few inves-
tigators with a small number of patients and has not been
well documented in the medical literature (6, 7), The opti-
mal timing of breath testing after the discontinuation of
these agents has yet to be established. This issue has clinical
importance with regard to the optimal performance of the
breath test. In addition, this issue has practical relevance,
inasmuch as patients taking omeprazole with ongoing dys-
peptic symptoms often are unwilling to withhold their med-
ication.
In the current study, we investigated the effect of ome-
prazole on the accuracy of the ''^C-urea breath test. In
addition, we performed serial studies after the discontinua-
tion of omeprazole to determine the duration of the drug's
effect on the breath test. Finally, we questioned whether the
effect of omeprazole on the breath test was dose dependent.
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MATERIALS AND METHODS
Study population
Fifty-seven employees and patients (25 females and 32
males) were recruited from the outpatient clinics of the
University of Michigan Medical Center. All subjects were
more than 18 yr old and gave written informed consent.
Women of child-bearing age were not eligible for this study
because of the small doses of radiation associated with
"'C-urea breath testing. None of the subjects enrolled were
taking medications known to affect the ''^C-urea breath test
adversely (antibiotics, Pepto Bismol, carafate) or had a
history of previous gastric surgery. All subjects were in
good general health, and a physical examination before
enrollment was normal. This protocol was approved by the
Institutional Review Board of the University of Michigan
Medical Center.
Effect of omeprazole on the sensitivity of the ''*C-urea
breath test
Those individuals interested in enrolling in the study
underwent a serology test for HP (Flex-sure, Smith, Kline
Diagnostics, San Jose, CA) or, if clinically indicated, an
upper endoseopy with gastric mueosal biopsy for CLO
testing (Tri-Med Specialties, Charlottesville, VA) and/or
histopathological examination. Those without evidence of
HP infection were excluded from further analysis. Those
found to have positive HP serology, CLO test, or histology
were asked to undergo a baseline '"C-urea breath test. Most
subjects enrolled were not taking omeprazole at the start of
the study. Those taking omeprazole when the study began
were asked to withhold their medication for at least 7 days
before the baseline breath test. Individuals who had negative
baseline breath tests were excluded from further study.
Those who had positive baseline breath tests were asked to
take omeprazole 20 mg/day for 14 days. Patients then un-
derwent repeat breath testing 1, 3, and 5 days after the
cessation of omeprazole therapy. Once a patient developed
a positive breath test, no further breath tests were performed
for this part of the protocol. The data obtained from these
studies were used to calculate the rate of false-negative
breath tests in patients recently taking omeprazole. In addi-
tion, the length of time during which the breath test re-
mained falsely negative was determined.
A number of individuals with positive baseline breath
tests remained positive after a 14-day course of omeprazole
20 mg/day. To address whether a higher dose of omeprazole
might lead to the development of a false-negative breath
test, these subjects were asked to take a 14-day course of
omeprazole at a dose of 40 mg/day (20 mg taken twice
daily). Repeat breath tests with the same study end points
described above were then performed.
'''C-urea breath test
For the ''^C-urea breath test, we used the protocol devel-
oped by Tri-Med Specialties. Subjects fasted for at least 6 h
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prior to the study. On the day of the test, a baseline breath
sample was obtained by instructing subjects to blow slowly
through tubing fitted with a one-way valve into a hyamine-
containing solution. A pH-sensitive color change from blue
to clear indicated the collection of an adequate breath sam-
ple. Subjects next ingested a capsule containing ''*C-urea (1
jLtCi). Repeat breath samples were collected 10 and 20 min
after the ingestion of ''*C-urea. Upon completion of the
study, the breath samples were analyzed for the presence of
'"̂ C with a scintillation counter (Beckman LS-7800). A
positive test was defined as > 200 dpm, indeterminate test
100-200 dpm, and negative test < 100 dpm. These criteria
have recently been validated by Peura and colleagues. They
found a cut-off of > 200 dpm for a positive study to be 97%
sensitive and 95% specific (8). Using these criteria, all
positive studies were found to have > 200 dpm at the
10-min sample.
Statistical analysis
The false-negative rate (I^R) was calculated with the
formula: FNR = FN/TP + FN, where TP = true positives
and FP = false positives. Disintegrations per minute were
expressed as means ± SEM. Mean dpm values were com-
pared by Student's / test for paired observations.
RESULTS
Effect of omeprazole on the sensitivity of the '''C-urea
breath test
Of the 57 subjects screened, 13 (22.8%) had active HP
infection, the diagnoses being based on gastric mueosal
histology, CLO testing, or serological testing, followed by
confirmatory ''*C-urea breath testing. Of the 13 subjects
enrolled, five were female and eight were male (mean age
47.3 yr). Ten of 13 subjects underwent a baseline ''^C-urea
breath test. Three subjects with positive histology for HP
chose to omit the baseline breath test and proceed directly to
therapy with omeprazole. Eight of 10 subjects with baseline
breath tests experienced a significant decrease in expired
"*C02 (1900 ± 214 dpm at baseline, 536 ± 161 dpm after
omeprazole 20 mg/day, p < 0.01). Breath test data from all
subjects enrolled are presented in Table 1. Five of 13 sub-
jects with active HP infection had a negative breath test (<
200 dpm) after 14 days of therapy with completion of
omeprazole 20 mg/day. This yielded a false-negative rate of
38.5%. Three of the five subjects who had a negative breath
test 1 day after omeprazole reverted to a positive breath test
within 3 days of completing therapy. All five subjects neg-
ative 1 day after omeprazole had a positive breath test 5 days
after cessation of the drug.
Five of eight subjects with a persistently positive breath
test after omeprazole 20 mg/day agreed to undergo a 14-day
course of omeprazole 40 mg/day (20 mg taken twice daily).
Four of five subjects developed a significant decrease {p <
0.02) in '''COj excretion after omeprazole (Table 2). One of
five developed a negative breath test, and two others had
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TABLE 1
Results of baseline breath tests and serial breath tests performed after a























































* Results are expressed in dpm. Omeprazole led to a marked decrease
in '"002 excretion in 8/10 patients with baseline breath test results (p <
0.01). Results of serial breath testing 1, 3, and 5 days after omeprazole are
also presented. A positive test was defmed as >200 dpm, indeterminate test
100-200 dpm, and negative test <100 dpm. All subjects had a positive
breath test 5 days after cessation of omeprazole.
TABLE 2
Results of breath testing (dpm) in five subjects retreated with




























* Five subjects who had persistently positive breath tests despite taking
omeprazole 20 mg/day X 14 days agreed to be retreated with omeprazole
at a dose of 40 mg/day X 14 days. This table documents results of breath
testing (dpm) after omeprazole 40 mg/day. A positive test was defmed as
>200 dpm, indeterminate test 100-200 dpm, and negative test <100 dpm.
Four of five subjects experienced a significant decrease in '''CO2 excretion
after this dosage of omeprazole (p < 0.02). One of five developed a
negative breath test after the higher dosage of omeprazole. All five subjects
had a positive breath test 5 days after stopping omeprazole.
indeterminate results after omeprazole 40 mg/day. Once
again, all subjects had a positive breath test within 5 days of
discontinuing the higher dosage of omeprazole.
DISCUSSION
Urea breath tests are emerging as important tools in the
diagnosis of HP (4). Versions of the urea breath test that use
''̂ C and '^C are currently undergoing clinical trials in the
United States in the hopes of achieving FDA approval. Once
FDA approved, these tests will be widely available for use
by clinicians. Thus, the establishment of optimal conditions
for performing the test will be very important.
Omeprazole, a benzimidazole proton pump inhibitor, has
been shown to have anti-HP properties and has been incor-
porated into a number of treatment regimens for this organ-
ism (9,10). Proton pump inhibitors can inhibit the growth of
HP in vitro (11). These agents may also directly inhibit HP
urease activity (12). McGowan et al (5) recently reported
that omeprazole inhibited the growth of HP at low pH levels
by a urease-independent mechanism. This effect was also
observed with strains of bacteria otber than HP. They spec-
ulated that HP might exert its toxic effects via binding of
bacterial ATPases. The possibility that proton pump inhib-
itors exert anti-HP effects through mechanisms independent
of their ability to raise gastric pH may explain why hista-
mine 2-receptor antagonists in standard doses do not ad-
versely alter the accuracy of the ''*C-urea breath test (Barry
Marshall, personal communication). The effect of high-dose
histamine 2-receptor antagonist therapy on the "'C-urea
breath test has not been established.
From a more clinical standpoint, Weil et al (6) treated 24
HP-infected patients with omeprazole at doses of 20 or 40
mg/day for 28 days. They then assessed clearance (absence of
HP at the end of treatment) and eradication (absence of HP > 1
month after therapy), using the "*C-urea breath test. Three of
12 and 0/12, respectively, experienced clearance and eradica-
tion of HP after therapy with omeprazole at a dose of 20
mg/day. The numbers for clearance and eradication were 6/12
and 1/12, respectively, after omeprazole 40 mg/day (6). A more
recent publication found that therapy with omeprazole alters
results of '^C-urea breath testing. In this study, 4/29 (13.8%)
developed a negative breath test ('^COj excretion < 5 per mil)
immediately after taking omeprazole 40 mg/day for 4 wk. All
four of these patients had a positive breath test 2 wk after
discontinuing omeprazole. The authors also used serial histo-
logical evaluations to demonstrate an improvement in antral
gastritis and shift in density of Helicobacter organisms to the
more proximal parts of the stomach after therapy with ome-
prazole (7).
These studies provide evidence that omeprazole ad-
versely affects the accuracy of the '"C-urea breath test.
However, they do not provide insight into the duration of
this effect. Our study confirmed that recent treatment with
omeprazole can lead to a false-negative breath test. Five of
13 (38.5%) subjects with active HP infection were found to
have a negative breath test after 14 days of therapy with
omeprazole 20 mg/day. In addition, if we assume that the
level of expired "*C02 provides a semi-quantitative measure
of HP urease activity, it is noteworthy that 8/10 subjects
with a baseline breath test experienced a significant de-
crease in expired '"^COj immediately after omeprazole 20
mg/day, (p < 0.05). This observation suggests that ome-
prazole exerted a suppressive effect in the vast majority of
subjects tested. Three of five subjects with a negative breath
test 1 day after omeprazole tested positive within 3 days of
discontinuing omeprazole. All five subjects negative 1 day
after omeprazole had a positive breath test 5 days after
stopping the drug. Five of eight subjects who had a persis-
tently positive breath test after omeprazole 20 mg/day
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agreed to undergo a 14-day course of omeprazole 40 mg/day
(20 mg taken twice daily). One of five developed a negative
breath test, and two others had indeterminate results after
omeprazole 40 mg/day. Once again, all subjects had a pos-
itive breath test 5 days after cessation of omeprazole. ''*C02
excretion after the higher dose of omeprazole was signifi-
cantly lower than that observed after the course of omepra-
zole 20 mg/day, suggesting that omeprazole's effects were
dose dependent.
This study has important practical implications for cen-
ters performing the ''^C-urea breath test. Certainly, many
patients taking omeprazole for ongoing dyspeptic symptoms
prefer to withhold their medication only as long as abso-
lutely necessary. Our data suggest that omeprazole should
be withheld for a minimum of 5 days before the study. The
concurrent use of an antibiotic or bismuth with omeprazole
would necessitate a longer waiting period (>28 days) before
C-urea breath testing. The newly approved proton pump
inhibitor, lansoprazole, probably will also effect the accu-
racy of the ''^C-urea breath test. However, whether the
magnitude or timing of this effect will be the same as that
observed with omeprazole remains to be established. Intu-
itively, there is no reason why these data could not also be
applied to the '•'C-urea breath test, although a study to
confirm our results would be of interest.
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